Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice

Area of Science:

• Pharmacology
• Immunology
• Microbiology

Background:

• Gram-negative bacterial infections trigger inflammation and pain.
• Lipopolysaccharide (LPS) is a key component of Gram-negative bacteria, inducing these responses.
• Diosmin, a citrus flavonoid, possesses known antioxidant and anti-inflammatory properties.

Purpose of the Study:

• To investigate the efficacy of diosmin in mitigating nonsterile inflammation and pain induced by LPS.
• To evaluate diosmin's impact on LPS-induced hyperalgesia, peritonitis, and associated molecular pathways.

Main Methods:

• Utilized a nonsterile mouse model of inflammation and peritonitis induced by LPS.
• Assessed pain using mechanical and thermal hyperalgesia tests, and static weight bearing.
• Quantified neutrophil recruitment via myeloperoxidase activity and leukocyte counts.
• Measured oxidative stress markers, including ROS and superoxide anion production.
• Analyzed cytokine levels (IL-1β, TNF-α, IL-6) and NF-κB activation.

Main Results:

• Diosmin dose-dependently reduced LPS-induced mechanical and thermal hyperalgesia.
• Diosmin significantly decreased neutrophil and leukocyte recruitment in paws and peritoneal exudates.
• Treatment with diosmin attenuated LPS-induced oxidative stress and pro-inflammatory cytokine production.
• Diosmin inhibited NF-κB activation in response to LPS.

Conclusions:

• Diosmin demonstrates significant efficacy in reducing LPS-induced inflammation and pain in a nonsterile model.
• The anti-inflammatory and analgesic effects of diosmin are linked to its ability to reduce oxidative stress and inhibit NF-κB signaling.
• Diosmin represents a promising therapeutic candidate for managing inflammation and pain associated with Gram-negative bacterial infections.